Pharmaceutical firm Cytogen posted fourth-quarter revenue of $3 million, up 15% compared with the fourth quarter of 2000. For the period (end-December 31), the Princeton, NJ-based vendor had a net loss of $2.6 million, compared with a net loss of $2.4 million in the fourth quarter last year.
In quarterly developments, Cytogen said that sales of BrachySeed I-125 climbed 75% over the previous quarter. For the year, Cytogen had revenue of $11.7 million, up 12% compared with the $10.5 million reported in 2000. The firm had a net loss of $12.1 million, compared with a net loss of $27.3 million in 2000.
In line with the declining market for colorectal applications of its OncoScint radiopharmaceutical agent, Cytogen said it has decided to decrease its emphasis on OncoScint and focus on its prostate cancer product line.
By AuntMinnie.com staff writersFebruary 13, 2002
Related Reading
Cytogen raises $8 million, January 23, 2002
Cytogen trims loss in Q3, November 7, 2001
Cytogen net loss widens in Q2 despite revenue gains, August 7, 2001
Cytogen builds executive team, June 11, 2001
Cytogen turns in revenue gains, April 27, 2001
Copyright © 2002 AuntMinnie.com
